Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis Vimal pandey, Nikhil Ranjan, Parimala Narne & Phanithi Prakash Babu Gliomas are incurable solid tumors with extremely high relapse rate and definite mortality. As gliomas readily acquire resistance to only approved drug, temozolomide (TMZ), there is increasing need to overcome drug resistance by novel therapeutics or by repurposing the existing therapy. In the current study, we investigated antitumor efficacy of roscovitine, a Cdk inhibitor, in combination with TMZ in vitro (U87, U373, LN 18 and C6 cell lines) and in vivo (orthotopic glioma model in Wistar rats) glioma models. We observed that TMZ treatment following a pre-treatment with RSV significantly enhanced chemo-sensitivity and suppressed the growth of glioma cells by reducing Cdk-5 activity and simultaneous induction of autophagy and Caspase-3 mediated apoptosis. Additionally, reduced expression of Ki67, GFAP and markers of angiogenesis (CD31, VEGF) was observed in case of TMZ + RsV treatments. Also, presence of reactive astrocytes in peri-tumoral areas and in areas around blood vessels was completely diminished in TMZ + RSV treated brain sections. Taken together, results in the current study provide evidence that RSV in conjunction with TMZ restricts glioma growth, reduces angiogenesis and also eliminates reactive astrocytes thereby preventing the spread of glioma to adjacent healthy brain tissues and thus might be more potent therapeutic option for glioma.
Glioblastomas (GBM) comprise majority of malignant central nervous system tumors, with an annual incidence of 3.19 per 100,000 in the United States and a post-diagnosis 5-year survival rate of less than 5% 1 . It remains one of the most aggressive solid tumors and is highly resistant to conventional chemotherapy incurring a high relapse rate with a meager mean life expectancy of less than 14 months in afflicted individuals 2 . Despite the standard of care regimen comprising surgery, radiotherapy, and chemotherapy providing a successful initial treatment, disease recurrence is inevitable and almost always fatal in majority of GBM cases. Therefore, improved therapy for GBM either by novel therapeutics or by supplementing existing therapy is imperative. To reduce high drug development costs, researchers have largely become interested in repurposing already approved drugs. Some examples of drug-repurposing studies for GBM include ibudilast, metformin and chloroquine 3 . Roscovitine (RSV), a cyclin-dependent kinase (Cdk) inhibitor, is a low molecular weight tri-substituted purine analogue which has been shown to inhibit Cdk 1, 2, 5, 7 and 9 at different concentrations [4] [5] [6] . It has been shown that RSV blocks the proliferation of various tumor cells, including that of neuronal cell types and tumor xenografts 7, 8 . Several pre-clinical and clinical studies suggest that RSV is a well tolerated oral agent with therapeutic potential against a range of tumor types 7, 9 . Low molecular weight of RSV facilitates its uptake, passage through blood brain barrier (BBB) and retention in brain 10 . It is apparently toxic to glioma cells while sparing normal astrocytes. It has been shown recently that sub-toxic concentrations of RSV can sensitize glioma cells that over-express the anti-apoptotic Bcl-2 or Bcl-xL to tumor-related apoptosis-inducing ligand 11 . Although, RSV monotherapy in cancer clinical trials have not been very encouraging, information regarding its synergistic cytotoxicity with several anticancer agents in multiple cancer types is substantial 7 . In line with this, RSV in . Cdk5 plays a central role during synaptogenesis and neuro-transmission under physiological conditions [13] [14] [15] [16] . However, excessive Cdk5 activation can result in neuronal dysfunction and death by varied mechanisms leading to neurodegeneration 17, 18 . Increasing evidence substantiates the contribution of Cdk5 over expression in initiation of the DNA-damage response and DNA repair 19 . In many cancers Cdk5 inhibition or Cdk5 knockdown is shown to increase cytotoxicity and restore chemotherapeutic sensitivity [20] [21] [22] . Importantly, work by several groups suggests that Cdk5 correlates positively with glioma grades in human samples 23, 24 . Thus, it becomes exciting to hypothesize that Cdk5 inhibition may be a valid strategy to bypass the resistance to chemotherapy and radiation therapy in glioma.
Though a significant amount of information exists regarding antitumor efficacy and synergism of RSV with numerous anticancer agents, reports investigating the effect of RSV in glioma are scarce 25 . Therefore, we investigated the effect of RSV alone and in combination with TMZ in vitro and in vivo glioma settings. We observed that RSV per se exerted significant anti-proliferative effect on glioma cell growth and RSV pretreatment sensitized the glioma cells to cytotoxic effects of TMZ. Additionally, RSV also reduced the number of reactive astrocytes and their localization around blood vessels significantly thereby restricting the spread of glioma cells to the healthy parts of brain. Also, combination therapy of TMZ + RSV reduced the expression of angiogenic markers CD31 and vascular endothelial growth factor (VEGF) in vivo. Interestingly, we observed that the anti-proliferative effect of TMZ + RSV on glioma was partly mediated by Cdk5 inhibition induced autophagy in conjunction with Caspase-3 mediated apoptosis, as evidenced by an increased expression of autophagy and apoptosis markers and increased survival upon pretreatment with 3-methyladenine (3-MA, early stage autophagy inhibitor) and Z-DEVD FMK, a Caspase-3 inhibitor.
Results
Roscovitine inhibits proliferation and potentiates the cytotoxic effects of TMZ on glioma cells in vitro. Anti-proliferative activity of RSV has been confirmed in several tumor cell lines but reports regarding glioma are scarce. There is a single study reporting growth inhibition upon RSV treatment in several glioma cell lines. To confirm the effect of RSV on glioma cell lines we treated U87, U373 and LN18, human glioma cell lines and C6, a rat glioma cell line with increasing concentrations (1 µM to 40 µM) of RSV. We observed a dose-dependent decrease in percent survival of all the three cell lines tested. U87 cells showed a significant dose-dependent decrease in percent survival from approximately 93% to 40% whereas in U373 cells the decrease was from 98% to 53% with an increasing dose from 1 µM to 40 µM (Fig. 1A) . C6 cells showed a decrease from 100% to 18% in response to treatment with increasing dose of RSV from 1 to 40 µM (Fig. 1A) . The decreased percent survival was statistically significant at 10 µM, 20 µM and 40 µM RSV (p < 0.005) concentrations. The decreased percent survival was statistically significant at 10 µM, 20 µM (p < 0.05) and 40 µM (p < 0.005) concentrations of RSV in U87 cells. Also in U373 cells, the decrease in cell viability was statistically significant at 10 µM (p < 0.05), 20 µM and 40 µM (p < 0.005) RSV concentrations. Similar results were also observed in LN 18 glioma cells ( Supplementary  Fig. 1A ). We further investigated the effect of RSV in combination with TMZ in these cells by MTT assay and long term colony formation assay. For these experiments we used TMZ concentration of 100 µM which represents the clinically relevant concentration of the drug 26 . We treated U87 and C6 cells with different concentration of RSV ranging from 0 to 40 µM followed by treatment with 100 µM TMZ. In U87 cells when combined drug treatment was given, we observed statistically significant reduction in percent survival in cells treated with 10 µM, 20 µM and 40 µM RSV (p < 0.005) as compared to TMZ alone treated cells (Fig. 1B) . As can be seen in Fig. 1B , reduction in cell viability was not statistically significant at all the concentrations tested. When compared to TMZ-alone treated cells, in C6 cells, significant reduction in percent survival with combination therapy was observed at concentrations of 5 µM, 10 µM, 20 µM and 40 µM (p < 0.005) of RSV. When compared to RSV-alone treated cells, potentiation of cytotoxicity in combination therapy was significant at 5 and 10 µM (p < 0.005) RSV concentrations in both the U87 and C6 cell lines. Potentiation of TMZ cytotoxicity with RSV concentration was also observed in LN18 cells at similar concentrations ( Supplementary Fig. 1B ). Based on isobologram analysis and combination index (CI) values, the enhanced cytotoxicity at TMZ concentration of 100 µM appears to be synergistic with a CI value of 0.7 in U87 cells ( Supplementary Fig. 1C ). These observations from MTT assay were complemented by long term cytotoxicity assay. As observed in Fig. 1C , significant reduction in the number of colonies was observed in cells treated with a combination of TMZ and RSV in both U87 and C6 cell lines (Fig. 1C) .
The colony formation assay confirmed that while both TMZ and RSV alone at experimental concentrations inhibited glioma growth, combination of TMZ with RSV had better anti-proliferative capacity in the glioma cell lines tested.
Roscovitine alone or in combination with TMZ decreases glioma progression in vivo.
Considering the significant anti-proliferative effect of RSV and TMZ + RSV in vitro, we tested its relevance in vivo. In vivo glioma model using C6 cell line was established in Wistar rats using stereotaxic apparatus. Development of tumor was confirmed by randomly selecting two rats and sacrificing them on 7 th day after implantation of tumor. Brains of these rats were dissected, processed and subjected to H and E staining and observed under the microscope to confirm the presence of tumor ( Fig. 2A) .
Tumor bearing rats were divided into four groups and were vehicle untreated (Control) or treated with TMZ, RSV or a combination of both the drugs (RSV + TMZ). TMZ was administered at a dose of 10 mg/kg/day and RSV was given 30 min prior to TMZ at a dose of 25 mg/Kg/day (on alternate days in 3 doses). Rats were then sacrificed on 8 th day from the start of the treatment (14 th day of tumor implantation) and brains were dissected and stored in 4% PFA followed by dehydration in sucrose gradients. Further, these brains were sectioned using www.nature.com/scientificreports www.nature.com/scientificreports/ cryo-microtome and sections were subjected to H and E staining or IHC staining. Histological analysis with H and E staining of these sections showed significantly decreased cell numbers in tumor sections from TMZ, RSV and TMZ + RSV treated rats when compared to the control vehicle treated rats. However, as can be visualized in Fig. 2A , maximum inhibition of tumor proliferation was observed in TMZ + RSV treated group. In fact, the cell density in tumor sections from this group was almost similar to non-tumor region. H and E stained tumor sections in the vehicle-treated rats showed presence of severe haemorrhages in blood vessels which were not observed in any of the treated groups (TMZ, RSV and TMZ + RSV) (Fig. 2B ). Immunohistochemical staining for Ki67, which is a known marker of active proliferation in cancer cells including glioma cells, also confirmed a significantly reduced progressive potential of C6 cells in tumor sections from treated rats (TMZ, RSV and TMZ + RSV) as compared to vehicle-treated rats (Control). Clear significant nuclear positivity for Ki67 was observed in tumor sections from vehicle-treated rats whereas negligible nuclear staining for Ki67 was observed in tumor sections of all the three treated groups ( RSV treatment alone or in combination with TMZ decreases reactive astrocytes and reduces angiogenesis. GFAP is a marker for glial cells. Immunohistochemical staining with GFAP usually shows cytoplasmic staining in glial sections. However, according to literature, GFAP staining can also be used as a marker for reactive astrocytes, as the reactive astrocytes stain intensely positive for GFAP and their long and short processes also stain positive for GFAP 27 . Interestingly, the sections of tumors from control untreated rats showed overwhelming abundance of reactive astrocytes in peritumoral areas (Fig. 3Aa, Supplementary Table 2 ). This observation is also supported by gemistocytic nuclear morphology in these sections which is specific for reactive astrocytes (Fig. 3Ab) . Reactive astrocytes were also conspicuous around the blood vessels in tumor sections from vehicle treated rats (Fig. 3Aa , Black arrows). Reactive astrocytes potentiate tumor aggressiveness, possibly by augmenting inflammatory responses crucial to the progression and spread of tumor. The number of reactive astrocytes was relatively reduced in TMZ treated tumor sections but surprisingly, in RSV treated sections, they www.nature.com/scientificreports www.nature.com/scientificreports/ were negligible. Similarly, in tumor sections which received combination therapy of TMZ and RSV, the reactive astrocytes were totally reduced in size and numbers (Fig. 3Aa) .
Angiogenesis is an important survival strategy of tumors that enables them to obtain the supply of nutrients directly from the blood. GBM is classified as a highly vascularised tumor. To check whether current treatment regimes had any effect on angiogenesis in gliomas, we checked for the expression of CD31 and VEGF, which are important angiogenic markers for glioma. We observed a significant decrease in the expression level of CD31 in TMZ, RSV and TMZ + RSV treated tumor sections when compared to control tumor sections (Fig. 3B,  Supplementary Table 3 ). Also, in control tumors, prominent staining of CD31 around the blood vessels was observed (Black arrows, Fig. 3B ). However, expression pattern of VEGF in these tumors was observed to be slightly variable. Although TMZ and RSV treated tumor sections showed positive VEGF staining, the intensity of staining in TMZ-treated and RSV-treated tumor sections was much reduced when compared to vehicle-treated control tumor sections. In TMZ + RSV treated tumor sections, very weak VEGF staining was observed (Fig. 3C , Supplementary Table 4 ).
Cdk5 inhibition decreases glioma cell survival and induces autophagy. Existing literature demonstrates that Cdk5 is highly up-regulated in gliomas when compared to normal human astrocytes. Also, as described earlier, RSV is known to effectively inhibit Cdk5 activity 28 . To investigate the role of Cdk5 expression and activity in glioma cells, SiRNA mediated knockdown approach was used. Interestingly, SiRNA-mediated knockdown of Cdk5 resulted in a notable dose-dependent decrease in percent survival in U87 and U373 cells. A significant decrease of approximately 60% (p < 0.001) in percent survival of U373 cells was observed whereas in U87 percent survival decreased by 25% (p < 0.05). Thus, it was observed that Cdk5 expression is crucial to the survival of these glioma cell lines and down regulation of Cdk5 levels by specific SiRNA reduces the proliferation of U87 and U373 cells (Fig. 4A) . Reports suggest a possible role of Cdk5 in autophagy regulation in neurons 29 . We therefore investigated the possible role of Cdk5 in autophagy regulation in glioma cell lines. For this, we checked the expression level of LC3B and Beclin 1 after SiRNA mediated knockdown of Cdk5 in U87 www.nature.com/scientificreports www.nature.com/scientificreports/ and U373 cells. Interestingly, we observed that knockdown of Cdk5 was associated with significantly increased expression of both LC3B and Beclin 1, well known autophagy markers (Fig. 4B, Supplementary Fig. 2 ). Thus, similar to neuronal cells, there appears to be a direct autophagy inhibitory function of Cdk5 in glioma cells. To check whether Cdk5 regulates autophagy and not vice versa, we induced autophagy in U87 and U373 cells by treatment with rapamycin, which is an established inducer of autophagy. Following treatment with rapamycin, we checked phospho-Cdk5 (pCdk5) levels in U87 and U373 cells treated with rapamycin. Phosphorylation levels of Cdk5 are an indirect measure of its kinase activity. Interestingly, there was a reduced Cdk5 activity in rapamycin treated cells as evidenced from decreased expression of pCdk5 in rapamycin treated cells. 1 µM concentration of rapamycin in both the cell lines inhibited pCdk5 levels but decrease was more marked in U373 cells which shows that U87 cells are more resistant to induction of rapamycin induced autophagy (Fig. 4C, Supplementary Fig. 2 ). Immunoblotting for Beclin 1 indeed showed a higher increase in the protein expression levels in U373 cells when compared to U87 cells (Fig. 4C, Supplementary Fig. 2 ). Based on these results, it appears that autophagy and Cdk5 activity are co-ordinately regulated by each other and Cdk5 has a complex role in autophagy regulation in glioma cells.
Temozolomide treatment down regulates Cdk5 activity and induces autophagy in glioma cells in vitro. TMZ is the only chemotherapeutic drug currently in use for glioma patients. TMZ, a DNA damaging agent, is known to induce apoptosis and autophagy in glioma cells. Increasing evidence substantiates the contribution of Cdk5 in initiation of the DNA-damage response (DDR), DNA repair and autophagy. Thus, we explored the effect of TMZ treatment on Cdk5 activity and autophagy in glioma cells in vitro. For this we first estimated the IC50 drug concentration of TMZ in U87 and U373 cells by MTT assay. We observed that U87 cells were more resistant to TMZ treatment with an IC50 value of 650 µM and U373 cells were sensitive with an IC50 value of www.nature.com/scientificreports www.nature.com/scientificreports/ 375 µM (Fig. 5A) . At respective 1/2 IC50 and IC50 concentrations, we observed a dose dependent decreased expression of pCdk5 in both the cell lines (Fig. 5B) . In addition, we checked the expression levels of p35, an effector protein of Cdk5 under these conditions. We observed a down regulation of p35 expression upon treatment with different TMZ concentrations. However, the decrease in p35 expression was not dose-dependent (Fig. 5B) . Following this observation we checked the mRNA expression of p35 and Cdk5 in U87 and U373 cells treated with indicated concentrations of the drug. However, we did not find any significant changes at mRNA levels upon treatment with TMZ (Fig. 5C) . Thus, it appears that treatment with TMZ does not alter transcriptional levels of Cdk5 but mainly affects the activity of Cdk5 by modulating the activating mechanisms like phosphorylation of Cdk5.
To validate autophagy induction in response to TMZ in our model system, we checked for the LC3B expression by immunofluorescence. In line with the existing literature, as depicted clearly in single cell images and quantification data, we observed that U87 and U373 cells treated with TMZ showed an increase in LC3 staining compared to control cells (Fig. 6, Supplementary Fig. 3 ).
Enhanced cytotoxicity of TMZ + RsV in vitro and in vivo is mediated by increased autophagy and apoptosis. As described in in vitro results, TMZ in glioma cells induces autophagy. Further, Cdk5 inhibition in glioma cells also leads to increased autophagy. Autophagy has been proposed as one of the cell death mechanism in several cases. Thus it is plausible that a cumulative increase in autophagy might be involved in increased cytotoxicity of TMZ when used in combination with RSV. Thus, we checked the expression of apoptosis and autophagy-related markers in C6 cells under control, TMZ, RSV and TMZ + RSV treatment conditions. First, we checked the status of Cdk5 activation in response to these drug treatments. We observed a reduced expression of pCdk5 in TMZ and RSV treated cells when compared to control cells. However, as can be observed, maximum inhibition of Cdk5 activity was observed in case of combination treatment with TMZ + RSV (Fig. 7A) . Cdk1 is another cyclin dependent kinase which is known to be affected by RSV treatment. The protein expression levels of Cdk1 were reduced in RSV treated cells. However, the decrease in TMZ and TMZ + RSV treated cells was not significant. We observed an increased Caspase 3 cleavage in TMZ treated cells when compared to control cells. Caspase 3 cleavage was also observed in RSV and TMZ + RSV treated cells. Importantly, we observed a progressive increase in LC3B expression and cleavage in TMZ, RSV and TMZ + RSV treated cells. We also observed an increased expression of Beclin1, a known positive regulator of autophagy in RSV and TMZ + RSV treated cells (Fig. 7A) . To validate the in vivo relevance of these findings we performed IHC staining for LC3B in the tumor sections from vehicle treated and drug (s) treated rats. We observed increased autophagy as inferred from IHC staining for LC3B in the treated groups as compared to untreated section. TMZ-treated tumor sections showed moderate positivity for LC3B whereas RSV and TMZ + RSV treated tumor sections showed a signficant www.nature.com/scientificreports www.nature.com/scientificreports/ increase in LC3B staining when compared to vehicle treated tumor sections (Fig. 7B, Supplementary Table 5 ). To further confirm the involvement of autophagy in TMZ + RSV mediated cell death, we treated C6 glioma cells with various autophagy inhibitors. For this C6 cells were first pre-treated with either 3MA (1 mM), BafA1 (10 nM) or CQ (20 µM) for 2 h followed by treatment with either TMZ (100 µM), RSV (20 µM) or TMZ + RSV for 72 h. We observed that treatment with 3MA, which inhibits autophagy at early stages, was able to partially rescue C6 cells from RSV and TMZ + RSV mediated cell death. There was an increase in percent survival in 3MA pre-treated + TMZ + RSV treated cells (43%) when compared to only TMZ + RSV treated cells (28%) (Fig. 7C) . Also, 3MA treatment reduced the percent cell death in RSV treated cells. Surprisingly, 3MA pre-treatment was not able to rescue cells in only TMZ treated cells. Also, pre-treatment with late stage autophagy inhibitor BafA1 or CQ was unable to revert the cell death. In fact, there was an enhanced cell death in BafA1 or CQ pre-treated cells ( Supplementary Fig. 4A and B) . As we observed only partial reversal of cell death by treatment with 3MA and also based on the observation that there is an increase in Caspase-3 cleavage in all the treated conditions, we also checked the effect of Caspase-3 inhibitor and total Caspase inhibitors on the percent survival of C6 cells treated with TMZ, RSV or TMZ + RSV. Not surprising, we again observed a partial reversal of cell death in TMZ + RSV treated cells which were pre-treated with Caspase-3 inhibitor (Fig. 7D) . However, this was not observed in cells pre-treated with total Caspase inhibitor ( Supplementary Fig. 4C ). Thus, increased cell death in combination therapy of TMZ + RSV could be attributed to a combined effect of increased autophagy and Caspase-3 dependent apoptosis in these cells as evident from in vitro and in vivo data described.
Discussion
TMZ is the only chemotherapeutic drug currently in use for glioma patients. However, drug resistance is a major challenge for patients undergoing chemotherapy with TMZ. From promising preclinical evidence, several monotherapy alternatives to treat these tumors have been evaluated in clinical trials. However, these single targeted therapies have not shown great promise in human trials due to acquired resistance of gliomas to these monotherapies. In such scenario, synergistic multidrug targeting might allow better therapeutic outcomes 30 . In the current study, we tested the aforementioned hypothesis using RSV in combination therapy with TMZ for glioma 7, 9 . (2) Owing to its low molecular weight and structural similarity with purines, it can readily cross blood brain barrier and is efficiently retained in brain at concentrations which are cytotoxic to glioma cells 10 . (3) Additionally, RSV has demonstrated synergistic effects on the cytotoxicity of several anti-cancer agents by variable mechanisms 7 .
In the current study, we observed that upon treatment with increasing doses of RSV, significant dose-dependent inhibition of cell and tumor growth occurs in vitro and in vivo glioma models respectively. In fact, as a single agent, RSV at 40 µM concentration resulted in more than 50% inhibition of cell proliferation in these cell lines. However, previous studies have shown that sub toxic concentration of RSV for brain lies in the range of 5-20 µM 11 . Interestingly, we observed maximum potentiation of TMZ cytotoxicity at 10 and 20 µM RSV concentrations which lie within the sub-toxic concentration range. The sequential drug treatment regime followed in this study was based on already published literature advocating the maximum beneficial effect of RSV as a pretreatment 21 . Inhibition of cell growth in long term colony formation assay supplements our MTT data and majorly reveals that increased cytotoxicity of TMZ by RSV pretreatment is irreversible and persists even after withdrawal of drug. In keeping with in vitro findings, RSV potentiated the cytotoxic effects of TMZ in vivo. To start with, treatment with either TMZ or RSV were quite effective in inhibiting the proliferation of glioma tumor when compared to vehicle treated group. However, the inhibition of tumor growth was much lesser when compared to TMZ + RSV treated group of rats. In the rat glioma model, though TMZ was able to suppress the growth of tumor cells, complete inhibition was far from being reached at the dosage used. Similar was the case for RSV monotherapy. Nevertheless, combination therapy of TMZ + RSV was potentially effective in near-complete inhibition of tumor growth as evidenced by cellular density and morphology together with Ki67 IHC staining.
In an attempt to identify the possible mechanisms involved in this enhanced inhibition of tumor growth in TMZ + RSV treated rats, we checked for the presence of reactive astrocytes (an essential feature of aggressive gliomas) and angiogenesis. Reactive astrocytes create an inflammatory microenvironment in the areas surrounding the tumor and help in progression and spread of tumor by activating MMPs which degrade extracellular matrix and eventually help in the spread of tumor to adjacent healthy areas in case of brain tumors 27 . In accordance with previous reports, IHC with GFAP revealed a dense population of reactive astrocytes in the peri tumoral region and around the blood vessels in control tumor section 27, 31 . Surprisingly, treatment with RSV and TMZ + RSV showed almost complete elimination of reactive astrocytes from peri-tumoral areas and blood vessels. In addition to reducing the population of reactive astrocytes, treatment with TMZ, RSV and TMZ + RSV also resulted in highly reduced angiogenesis as depicted by the IHC analysis of angiogenic markers, CD31 and VEGF in tumor sections. In response to the needs of nutrients and oxygen from the blood to grow and spread, angiogenesis is a process that occurs frequently in tumor regions. In the case of GBM, there is a high proliferative activity with infiltration into the surrounding tissues, since it is among the most highly vascularized tumors. Reports by Yushan et al. 23 , and Liu et al. 24 , show that Cdk5 is highly up-regulated in gliomas as compared to normal astrocytes and hence might be involved in the tumorigenic potential and rapid proliferation of glioma cells. However, there are no reports demonstrating the effects of Cdk5 knockdown in gliomas. Based on the aforementioned reports we observed that knockdown of Cdk5 effectively reduced the viability of glioma cells. Another observation (previously unreported) in the current study is that direct knockdown of Cdk5 induces autophagy in glioma cell lines. Beclin 1 expression levels showed that U87 cells were more resistant to autophagy induction in response to rapamycin and were also resistant to TMZ treatment as depicted by higher IC50 value. However, they were observed to be more responsive to TMZ + RSV combination therapy and showed synergistic decrease in percent survival. The reduced activity and expression levels of pCdk5 and p35 were not associated with changes in mRNA expression. Our data is supported by recent literature which has implicated Cdk5 in negative autophagy regulation by inhibiting the Class3PI3K pathway in neurodegenerative conditions 32 . Based on our findings we speculate that Cdk5 and autophagy are intricately connected in GBM cells and in fact coordinately regulate each other. Regarding this, we observed that autophagy induction by rapamycin leads to decreased expression of pCdk5 and an increase in Beclin 1 protein expression levels in glioma cells. Our data also demonstrates that reduced Cdk5 activity and altered downstream signaling may be one of the mechanisms mediating the cytotoxic effects of TMZ in glioma cells.
In vitro immunoblotting for pCdk5 level confirms the inhibition of Cdk5 activity in response to TMZ or RSV treatments. Immunoblotting for apoptosis and autophagy markers demonstrate a clearly increased autophagy induction in the cells treated with RSV and TMZ + RSV. In GBM, TMZ induced autophagy is putative. Recent studies indicate that autophagy-related signature can be used as an independent predictor of survival outcomes in glioma patients and could be potential therapeutic target in glioma 33, 34 . Autophagy has basically been proposed as a cell survival mechanism under stress conditions. However, it has been shown that autophagy can perform seemingly opposite roles during tumorigenesis and chemotherapy as a pro-survival or a pro-death mechanism through mechanisms which are largely unknown 35 . With respect to autophagy induced by TMZ treatment, our results are largely in confluence with earlier studies which show that autophagy induced in TMZ monotherapy is largely cyto-protective 36 Fig. 7C . On the contrary, it was observed that autophagy can easily trigger cell death in case of combination treatment 37, 38 . With respect to the autophagy induced in case of RSV and TMZ + RSV combination treatment, our study undoubtedly supports the concept of autophagy mediated cell death. In line with this, in vivo immuno-staining of tumor sections with LC3B antibody, and increased survival in cells pretreated with 3MA confirmed our in vitro findings concerning autophagy as one of the mechanisms of cell death in glioma cells after treatment with RSV and TMZ + RSV combination therapy. However, in the current treatment regime autophagy is definitely not the sole cause of enhanced cytotoxicity for tumor cells. As can be inferred from partial increase in cell survival in case of Caspase-3 pretreatment followed by TMZ + RSV treatment, enhanced cytotoxicity in this case can be attributed to parallel increase in autophagy and apoptosis simultaneously. Recent literature shows that (2019) 9:5012 | https://doi.org/10.1038/s41598-019-41380-1 www.nature.com/scientificreports www.nature.com/scientificreports/ in addition to being an alternative mechanism to cell death when apoptosis is inhibited, autophagy in some cases can in fact, precede or act in parallel with apoptosis 39 . Similar case was observed by Ren et al., wherein FK-16, derived from the anticancer peptide LL-37, induced Caspase-independent apoptosis and autophagic cell death in colon cancer cells 40 .
To conclude, in the present study, for the first time, we pin down the growth-inhibitory impact of RSV and potentiation of TMZ cytotoxicity by RSV in in vitro and in vivo glioma models. We show that glioma growth inhibition can be attributed to simultaneous increase in autophagy and Caspase-3 dependent apoptosis, reduced angiogenesis and decreased number of reactive astrocytes thereby restricting the spread of GBM tumors to adjacent healthy tissue. We also provide preliminary evidence regarding coordinate regulation of autophagy and pCdk5 and reveal the direct involvement of pCdk5 in autophagy regulation and glioma cell death. Though further research is needed to understand mechanisms underlying Cdk5-mediated regulation of autophagy in glioma, our study definitely establishes this as a mechanism of RSV and TMZ + RSV mediated tumor growth inhibition. Thus, our work proposes the combination of temozolomide and roscovitine as a novel potential therapeutic possibility in glioma and other cancers associated with Cdk5 overexpression.
Material and Methods
Drugs and Chemicals. The drugs and inhibitors used for the current study viz., RSV and TMZ were purchased from Adooq Bioscience (USA). 3MA, Bafilomycin A1 (BaF-A1) and Chloroquine (CQ) were purchased from Sigma (Sigma Aldrich, MO, USA). Z-DEVD FMK and Z-VAD FMK were obtained from Calbiochem (Calbiochem, LaJolla, CA). 3-MA was directly dissolved in DMEM prior to use, CQ was dissolved in sterile water. Baf-A1, Z-DEVD FMK and Z-VAD FMK were dissolved in DMSO to prepare respective stock solutions.
Cells and Culture conditions. Human GBM cell lines (U87, U373, LN18) and rat glioma cell line C6 were obtained from National Centre for Cell Science (NCCS), Pune, and maintained in cell culture facility. Other cell culture related reagents were purchased from GIBCO-life technologies (NY, USA). Cells were routinely cultured in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, NY, USA), penicillin (100 U/ml) and streptomycin (100 mg/ml) (Invitrogen Life Technologies, CA, USA) and maintained at 37 °C in a 5% CO 2 humidified incubator (Thermo Fisher Scientific, OH, USA).
MTT cytotoxicity assay. Cells were seeded at a density of 10,000 cells per well in 96 well plates and allowed to adhere for 24 h at 37 o C. Following this, cells were subjected to treatment with the drugs and/or inhibitors as per the experimental requirement. Control cells were treated with vehicle (DMSO). After 72 h of drug treatment, medium was removed and 50 µl of MTT (methylthiazole tetrazolium, 1 mg/ml in 1X PBS) was added to each well and further incubated for 4 h at 37 o C. Formazan crystals thus formed were solubilized in 50 µl iso-propanol and absorbance was measured at 570 nm using 630 nm as reference filter.
Long term survival assay. U87 or C6 cells were plated at a density of 2000 cells/well in 6 well plate and allowed to adhere for 24 h. Further, these cells were treated with either vehicle, drug and/or inhibitors as per the experimental requirements. After 72 h, medium was removed and fresh complete medium was added. Cells were allowed to grow for 14 days with the change of media after every 3 days. Thereafter, cells were fixed with 4% paraformaldehyde for 10 min and stained with 0.05% crystal violet for 30 min at room temperature. Images were taken using digital camera (Olympus, Tokyo, Japan).
Immunoblotting. The control and treated cells were washed with ice cold PBS thrice and lysed in ice cold cell lysis buffer (CST, MA, USA) with 1 mM PMSF. Briefly, the cells were scraped, collected and centrifuged at 3500 rpm for 5 min. Pellets were washed with ice cold PBS and lysed for 30 min on ice. The lysates were then passed through 27 gauge syringe and centrifuged at 12000 rpm for 20 min. Clear supernatants were stored at −80 °C. The protein concentration was quantified by Bradford protein assay reagent (Sigma-Aldrich, MO, USA). Equal amount of protein samples were resolved on 10-12% SDS-polyacrylamide gels and then transferred onto nitrocellulose membrane (GE Healthcare, UK). The membranes were blocked with 5% non-fat milk or 3% BSA and further probed with respective primary antibodies at 1:1000 dilution overnight at 4 °C. Blots were then washed and probed with respective HRP-conjugated secondary antibodies at a dilution of 1:2000. The blots were developed using luminescence detection reagents (Thermo Scientific, IL, USA). Whenever required the blots were stripped and reprobed. Otherwise, gels run in duplicate were probed for required proteins.
RNA isolation, cDNA synthesis and Semi-quantitative PCR. Total cellular RNA was extracted using TRIzol reagent (Sigma-Aldrich, MO, USA) according to manufacturer's instructions. One microgram of total RNA was converted to cDNA using cDNA synthesis kit (Takara Bio, USA) which was subsequently used for semi-quantitative PCR. The primer pairs used were as follows: Cdk5 5′-GGG AAG GCA CCT ACG GAA CTG-3′ (F), 5′-GGC GGA ACT CGG CAC ACC-3′ (R); p35 5′-ACG GTG CTG TCC CTG TCT T -3′ (F), 5′-TGG CGT TCT TGC TGT TCT GT-3′(R) and GAPDH 5′-TGA CCC CTT CAT TGA CCT CA-3′ (F), 5′-GAG ATG ATG ACC CTT TTG GCT-3′ (R). The annealing temperature used for all the primers was 58 °C.
www.nature.com/scientificreports www.nature.com/scientificreports/ Immunofluorescence. Glioma cells, approximately 1 × 10 4 cells were plated on coverslips in 24 well plate and allowed to grow for 24 h. Cells were then treated with desired concentrations of TMZ for 72 h. The medium was removed from the wells and cells were washed thrice with 1X ice cold phosphate buffered saline (PBS). After that the cells were fixed with 4% PFA for 15 min at room temperature. Cells were then washed with PBS twice, followed by membrane permeabilization with ice cold acetone and methanol (1:3) for 15 min at room temperature. Cells were then washed twice with ice cold PBS followed by blocking with 3% BSA for 1 h. Cells were then incubated with primary antibodies (1:100) in blocking solution at 4 °C overnight. After that cells were washed and incubated with secondary antibody (1:400) in blocking solution for 2 h at room temperature. After washing the cells thrice with ice cold PBS, cells were incubated with DAPI for 60 sec at room temperature. The cells were then again washed with ice cold PBS and coverslips were mounted on glass slides with mounting medium and analyzed by confocal microscope (Zeiss).
